Sinovac Biotech (SVA) AI Stock Analysis

• Market Cap: $460.27M
• Dividend Yield: 0%
• Average Volume (3M): 8.23K
• Price to Earnings (P/E): ―
• Beta (1Y): N/A
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 1,959
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 71,860,700
• 10 Day Avg. Volume: 8,227
• 30 Day Avg. Volume: 8,227
• PEG Ratio: 0.03
• Price to Book (P/B): 0.07
• Price to Sales (P/S): 1.44
• P/FCF Ratio: -15.46
• Enterprise Value/Market Cap: -1.10
• Enterprise Value/Revenue: -1.13
• Enterprise Value/Gross Profit: -1.95
• Enterprise Value/Ebitda: 83.96
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

No summary available

Positive Factors

Strong Balance Sheet

A strong balance sheet with high liquidity and low debt provides financial flexibility and stability, allowing the company to weather economic fluctuations and invest in growth opportunities.

Negative Factors

Revenue Decline

A significant decline in revenue indicates challenges in maintaining market demand and competitive positioning, which could impact long-term financial performance and growth prospects.

Sinovac Biotech Business Overview & Revenue Model

Company Description

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes v...

Read more

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes v...

How the Company Makes Money

Sinovac Biotech generates revenue primarily through the sale of vaccines to both government and private sector clients. The company's key revenue streams include domestic sales within China and international sales to countries around the world. Si...

Read more

Sinovac Biotech generates revenue primarily through the sale of vaccines to both government and private sector clients. The company's key revenue streams include domestic sales within China and international sales to countries around the world. Si...

Sinovac Biotech Financial Statement Overview

Breakdown	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	448.27M	1.49B	19.37B	510.62M	246.05M
Gross Profit	266.75M	808.30M	18.30B	443.44M	213.58M
EBITDA	-6.03M	183.10M	17.65B	221.76M	76.05M
Net Income	-99.92M	113.87M	8.47B	110.37M	44.93M
Balance Sheet
Total Assets	13.66B	14.11B	16.75B	1.90B	452.30M
Cash, Cash Equivalents and Short-Term Investments	11.22B	11.31B	13.42B	1.18B	202.99M
Total Debt	298.98M	74.67M	144.91M	136.39M	20.27M
Total Liabilities	1.64B	1.40B	2.87B	781.20M	100.10M
Stockholders Equity	8.71B	8.92B	9.33B	746.47M	294.02M
Cash Flow
Free Cash Flow	-41.69M	-1.17B	14.63B	351.66M	28.45M
Operating Cash Flow	104.00M	-770.75M	15.35B	479.31M	39.07M
Investing Cash Flow	-2.93B	-5.76B	-3.02B	-204.76M	-42.45M
Financing Cash Flow	-76.06M	-241.40M	-1.90B	592.57M	1.74M

Sinovac Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
SVA	―	$460.27M	―	―	0.00%	―	―
OCGN	52 Neutral	$577.10M	-5.95	-2626.38%	―	14.26%	-23.34%
KRRO	50 Neutral	$182.88M	-0.64	-115.95%	―	―	21.61%
VOR	47 Neutral	$755.67M	-0.19	72.70%	―	―	-1072.48%
FHTX	45 Neutral	$269.43M	-4.58	105.48%	―	-3.91%	37.89%